Mid Pharma Outlook
Mid Pharma Outlook
$3,000.00
Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
Publisher: Datamonitor Healthcare
- Description
- Contents
- Samples
Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth. On the positive side Allergan, Biogen Idec, Celgene, Gilead, and Shire enjoyed well above average percentage growth rates. Conversely, Forest, Lundbeck, Servier, UCB, and Warner Chilcott have posted, or are expected to post, sales declines through 2012, driven by generic sales erosion of flagship, blockbuster brands.
Despite the peer set’s aging product lines, a select group of companies will achieve great success from recent product launches. Gilead and its suite of fixed-dose combination HIV therapies will lead the way, as will Biogen Idec, which recently achieved regulatory approval for its orally active multiple sclerosis therapy Tecfidera (dimethyl fumarate).
In total, combined sales of each member of the mid pharma’s total prescription pharma sales are forecast to expand at a CAGR of 4.2% over 2011–17, with total sales expected to increase by over $19bn to reach $89bn by 2017.
TABLE OF CONTENTS
LIST OF FIGURES
LIST OF TABLES
4 EXECUTIVE SUMMARY
4 Key findings
4 Introduction
7 Mid pharma outlook to 2017
8 Mid pharma company performance to 2017
10 MID PHARMA OVERVIEW
10 Key findings
10 Mid pharma company analysis, 2011–17
14 Mid pharma product analysis, 2011–17
16 Mid pharma therapy area analysis, 2011–17
18 Mid pharma geography analysis, 2011–17
20 Mid pharma molecule type analysis, 2011–17
22
Mid pharma launch/core/expiry analysis, 2011–17
8 Figure 1: Mid pharma’s prescription pharmaceutical performance, sales ($m) and growth rate
(%), 2005–17
9 Figure 2: Mid pharma peer set performance ($m), 2005–17
12 Figure 3: Mid pharma peer set performance ($m), 2005–17
13 Figure 4: Mid pharma company growth drivers and resistors ($m), 2011–17
18 Figure 5: Mid pharma therapy area sales ($m), 2005–17
19 Figure 6: Mid pharma sales by geographic region ($m), 2005–17
21 Figure 7: Mid pharma molecule type focus (%), 2005–17
24 Figure 8: Mid pharma launch/core/expiry configuration ($m), 2011–17
25 Figure 9: Mid pharma company launch/core/expiry configuration ($m), 2011–17
4 Table 1: Mid pharma sales overview ($bn), 2011–12
10 Table 2: Mid pharma sales outlook ($m), 2011–17
14 Table 3: Mid pharma peer set product growth drivers and resistors ($m), 2011–17
16 Table 4: Mid pharma sales, by therapy area ($m), 2011–17
19 Table 5: Mid-pharma sales by geographic region ($m), 2011–17
20 Table 6: Mid pharma sales, by molecule type ($bn), 2011–17
23 Table 7: Mid pharma launch, core, and expiry portfolio overview ($m), 2011–17
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
2016 M&A Outlook 
Sign up to the